Jennifer E Yeh
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
9 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Jennifer E Yeh’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A171755 · Current
Licensed to practise in California · since 2021 · expires 2029-02-28 · Harvard Medical School.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$97,216
Medicare paid this office $97,216 for 643 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 209 | $24,647 | $78 |
| Short return visit (20+ min) | 282 | $18,190 | $52 |
| Destruction of skin growth, 1-14 growths | 137 | $9,346 | $57 |
| New patient visit (45+ min) | 93 | $8,796 | $95 |
| Destruction of precancer skin growth, 1 growth | 137 | $6,791 | $42 |
See all 19 services
| Return visit (30+ min) | 209 | $24,647 | $78 |
| Short return visit (20+ min) | 282 | $18,190 | $52 |
| Destruction of skin growth, 1-14 growths | 137 | $9,346 | $57 |
| New patient visit (45+ min) | 93 | $8,796 | $95 |
| Destruction of precancer skin growth, 1 growth | 137 | $6,791 | $42 |
| New patient visit (30+ min) | 108 | $6,660 | $62 |
| Long return visit (40+ min) | 14 | $4,039 | $126 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 19 | $3,460 | $173 |
| Biopsy of related skin growth, first growth | 95 | $2,214 | $21 |
| Removal of skin tag, 1-15 skin tags | 18 | $1,447 | $72 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $1,409 | $94 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 47 | $1,362 | $29 |
| Punch biopsy, first skin growth | 36 | $1,332 | $37 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 14 | $1,290 | $81 |
| Destruction of precancer skin growth, 2-14 growths | 102 | $865 | $2 |
| Injection into skin growth, 1-7 growths | 23 | $823 | $24 |
| Biopsy of related skin growth, each additional growth | 27 | $714 | $18 |
| Punch biopsy, each additional skin growth | 14 | $395 | $28 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $267 | $15 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 1-10 | None |
| Removal of skin lesions | 328 | More than 83% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 93 | More than 75% of doctors who do this |
Who their Medicare patients are
643 Original Medicare patients in 2024. Average age 73 · Under 65 7% · 85 and older 12% · Women 58% · Also on Medicaid 19% · Health risk score 1.21. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 57% · Diabetes 21% · Coronary heart disease 19% · Chronic kidney disease 18% · Cancer 15% · Depression 15% · Atrial fibrillation 14% · Heart failure 11% · COPD 10% · Dementia 6% · Stroke 6%.
The office billed $416,782, Medicare allowed $138,498 and paid $97,216; for 2,144 services of 40 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 643 | 2,144 | 73 | 1.21 | $416,782 | $97,216 |
| 2023 | 545 | 1,862 | 73 | 1.16 | $328,448 | $86,838 |
| 2022 | 418 | 1,614 | 74 | 1.27 | $291,603 | $72,871 |
| 2021 | 136 | 322 | 72 | 1.17 | $53,079 | $16,354 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Return visit (30+ min) | 193 | $21,344 | $82 |
| Short return visit (20+ min) | 203 | $13,281 | $54 |
| New patient visit (45+ min) | 117 | $13,048 | $112 |
| Destruction of skin growth, 1-14 growths | 145 | $10,709 | $63 |
| Destruction of precancer skin growth, 1 growth | 147 | $6,915 | $39 |
| New patient visit (30+ min) | 83 | $5,337 | $64 |
| Long return visit (40+ min) | 14 | $3,139 | $116 |
| Biopsy of related skin growth, first growth | 86 | $2,276 | $23 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 12 | $2,201 | $183 |
| Punch biopsy, first skin growth | 24 | $899 | $36 |
| Destruction of precancer skin growth, 2-14 growths | 104 | $888 | $2 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 28 | $784 | $28 |
| Biopsy of related skin growth, each additional growth | 20 | $676 | $20 |
| Injection into skin growth, 1-7 growths | 17 | $566 | $24 |
2022: 15 services
| Return visit (30+ min) | 169 | $19,728 | $82 |
| New patient visit (45+ min) | 107 | $10,900 | $102 |
| Short return visit (20+ min) | 121 | $7,193 | $53 |
| Destruction of skin growth, 1-14 growths | 107 | $6,857 | $55 |
| New patient visit (30+ min) | 95 | $5,551 | $58 |
| Destruction of precancer skin growth, 1 growth | 124 | $5,333 | $35 |
| Long return visit (40+ min) | 19 | $3,854 | $128 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 19 | $3,162 | $166 |
| Biopsy of related skin growth, first growth | 112 | $2,511 | $20 |
| New patient visit (60+ min) | 11 | $1,546 | $141 |
| Punch biopsy, first skin growth | 25 | $945 | $38 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 12 | $898 | $75 |
| Biopsy of related skin growth, each additional growth | 31 | $864 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 89 | $758 | $2 |
| Injection into skin growth, 1-7 growths | 13 | $304 | $19 |
2021: 8 services
| Return visit (30+ min) | 39 | $4,225 | $88 |
| New patient visit (45+ min) | 29 | $3,598 | $124 |
| New patient visit (30+ min) | 31 | $2,213 | $71 |
| Short return visit (20+ min) | 30 | $1,781 | $57 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,178 | $47 |
| Destruction of skin growth, 1-14 growths | 16 | $967 | $60 |
| Biopsy of related skin growth, first growth | 25 | $663 | $27 |
| Destruction of precancer skin growth, 2-14 growths | 18 | $158 | $2 |
Medicaid work
$36,054 in 2024
Medicaid paid $36,054 for 491 billed services this clinician did in 2024, up to 26 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 227 | $18,937 |
| New patient visit (45+ min) | 44 | $5,912 |
| Short return visit (20+ min) | 74 | $3,853 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 64 | $3,598 |
| Service | 68 | $2,802 |
| New patient visit (30+ min) | 14 | $954 |
| 2024 | 491 | 6 | 26 | $36,054 |
| 2023 | 505 | 6 | 33 | $21,713 |
| 2022 | 371 | 3 | 35 | $17,687 |
| 2021 | 64 | 3 | 18 | $3,106 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 308 | $14,499 |
| Service | 69 | $2,620 |
| New patient visit (45+ min) | 32 | $2,148 |
| Short return visit (20+ min) | 58 | $1,195 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 25 | $1,054 |
| Hospital outpatient clinic visit for assessment and management of a patient | 13 | $197 |
2022
| Return visit (30+ min) | 278 | $11,505 |
| New patient visit (45+ min) | 53 | $4,700 |
| Service | 40 | $1,482 |
2021
| New patient visit (45+ min) | 18 | $1,298 |
| Return visit (30+ min) | 33 | $1,262 |
| Service | 13 | $545 |
Drugs they prescribed that Part D paid
$803,411
Pharmacies billed $803,411 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,430) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
1,284 generic and fewer than 11 brand-name prescriptions · $803,411 in drug cost · 25 antibiotic prescriptions to 17 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Skyrizi | 13 | $253,464 | $19,497 |
| Dupixent | 32 | $119,091 | $3,722 |
| Dupixent | 24 | $86,542 | $3,606 |
| Otezla | 17 | $73,925 | $4,349 |
| Opzelura | 16 | $32,903 | $2,056 |
See all 32 drugs
| Skyrizi | 13 | $253,464 | $19,497 |
| Dupixent | 32 | $119,091 | $3,722 |
| Dupixent | 24 | $86,542 | $3,606 |
| Otezla | 17 | $73,925 | $4,349 |
| Opzelura | 16 | $32,903 | $2,056 |
| Clobetasol Propionate | 147 | $13,116 | $89 |
| Tacrolimus | 41 | $3,620 | $88 |
| Ketoconazole | 176 | $2,992 | $17 |
| Clindamycin Phosphate | 40 | $2,651 | $66 |
| Metronidazole | 29 | $2,279 | $79 |
| Mycophenolate Mofetil | 32 | $2,161 | $68 |
| Ciclopirox | 56 | $1,998 | $36 |
| Desonide | 38 | $1,722 | $45 |
| Tretinoin | 17 | $1,327 | $78 |
| Fluorouracil | 21 | $1,143 | $54 |
| Fluocinonide | 30 | $872 | $29 |
| Triamcinolone Acetonide | 87 | $843 | $10 |
| Hydroxychloroquine Sulfate | 33 | $811 | $25 |
| Econazole Nitrate | 29 | $743 | $26 |
| Minoxidil | 62 | $712 | $11 |
| Mupirocin | 58 | $551 | $10 |
| Clotrimazole | 15 | $540 | $36 |
| Hydrocortisone | 86 | $476 | $6 |
| Nifedipine Er | 17 | $369 | $22 |
| Hydroxyzine | 12 | $355 | $30 |
| Pentoxifylline | 17 | $344 | $20 |
| Doxycycline Hyclate | 21 | $234 | $11 |
| Betamethasone Diprop Augmented | 12 | $216 | $18 |
| Finasteride | 16 | $203 | $13 |
| Gabapentin | 18 | $168 | $9 |
| Methotrexate | 20 | $167 | $8 |
| Prednisone | 17 | $101 | $6 |
Year by year
| 2024 | 1,430 | 368 | 0% (0) | None | $803,411 |
| 2023 | 1,172 | 331 | 0% (0) | None | $716,618 |
| 2022 | 875 | 245 | 0% (0) | None | $514,639 |
| 2021 | 269 | 116 | 0% (0) | 17% | $299,456 |
| 2020 | 127 | 64 | 0% (0) | 21% | $78,689 |
| 2019 | 163 | 90 | 0% (0) | 25% | $13,308 |
| 2018 | 129 | 73 | 0% (0) | 16% | $17,090 |
| 2017 | 19 | None | 0% (0) | None | $4,102 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 28 drugs
| Skyrizi | 13 | $278,585 | $21,430 |
| Dupixent | 30 | $114,109 | $3,804 |
| Dupixent | 15 | $48,676 | $3,245 |
| Clobetasol Propionate | 114 | $13,533 | $119 |
| Fluocinonide | 60 | $2,993 | $50 |
| Metronidazole | 27 | $2,643 | $98 |
| Clindamycin Phosphate | 42 | $2,631 | $63 |
| Tacrolimus | 23 | $2,458 | $107 |
| Ketoconazole | 126 | $2,445 | $19 |
| Tretinoin | 15 | $2,098 | $140 |
| Calcipotriene | 11 | $1,984 | $180 |
| Ciclopirox | 48 | $1,897 | $40 |
| Betamethasone Dipropionate | 23 | $1,725 | $75 |
| Mycophenolate Mofetil | 17 | $1,473 | $87 |
| Clotrimazole | 13 | $1,319 | $101 |
| Triamcinolone Acetonide | 103 | $1,028 | $10 |
| Fluorouracil | 13 | $998 | $77 |
| Desonide | 23 | $956 | $42 |
| Mupirocin | 56 | $693 | $12 |
| Hydroxyzine | 26 | $637 | $24 |
| Econazole Nitrate | 15 | $423 | $28 |
| Prednisone | 38 | $407 | $11 |
| Hydrocortisone | 60 | $352 | $6 |
| Minoxidil | 33 | $340 | $10 |
| Doxycycline Hyclate | 14 | $309 | $22 |
| Finasteride | 16 | $229 | $14 |
| Methotrexate | 17 | $221 | $13 |
| Gabapentin | 12 | $191 | $16 |
2022: 22 drugs
| Dupixent | 28 | $98,398 | $3,514 |
| Dupixent | 20 | $69,430 | $3,471 |
| Xarelto | 11 | $9,536 | $867 |
| Clobetasol Propionate | 61 | $8,349 | $137 |
| Tacrolimus | 20 | $5,049 | $252 |
| Clindamycin Phosphate | 50 | $3,432 | $69 |
| Fluorouracil | 31 | $3,372 | $109 |
| Fluocinonide | 53 | $3,343 | $63 |
| Betamethasone Diprop Augmented | 23 | $2,155 | $94 |
| Ketoconazole | 70 | $1,284 | $18 |
| Doxycycline Hyclate | 18 | $859 | $48 |
| Mupirocin | 60 | $826 | $14 |
| Pentoxifylline | 12 | $759 | $63 |
| Triamcinolone Acetonide | 66 | $723 | $11 |
| Hydroxychloroquine Sulfate | 13 | $624 | $48 |
| Ciclopirox | 15 | $368 | $25 |
| Hydrocortisone | 37 | $285 | $8 |
| Mometasone Furoate | 11 | $227 | $21 |
| Prednisone | 25 | $226 | $9 |
| Hydroxyzine | 17 | $123 | $7 |
| Minoxidil | 11 | $102 | $9 |
| Terbinafine | 14 | $82 | $6 |
2021: 6 drugs
| Betamethasone Diprop Augmented | 19 | $1,183 | $62 |
| Fluocinonide | 14 | $782 | $56 |
| Ketoconazole | 38 | $664 | $17 |
| Clobetasol Propionate | 11 | $570 | $52 |
| Triamcinolone Acetonide | 14 | $187 | $13 |
| Hydrocortisone | 11 | $64 | $6 |
2020: 4 drugs
| Fluorouracil | 12 | $1,305 | $109 |
| Econazole Nitrate | 11 | $403 | $37 |
| Triamcinolone Acetonide | 14 | $260 | $19 |
| Ketoconazole | 16 | $240 | $15 |
2019: 5 drugs
| Betamethasone Dipropionate | 22 | $3,424 | $156 |
| Betamethasone Diprop Augmented | 15 | $1,882 | $125 |
| Clobetasol Propionate | 11 | $988 | $90 |
| Ketoconazole | 22 | $553 | $25 |
| Triamcinolone Acetonide | 19 | $223 | $12 |
Money from drug and device companies
$130 in 2024
| 2024 | 1 | 1 | None | $130 |
| 2020 | 1 | 1 | None | $80 |
| 2019 | 3 | 4 | None | $249 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $130 | 1 payment
|
See the published payment
| Janssen Biotech | Meals · 2024-03-07 | Tremfya | $130 |
See earlier years (2020, 2019)
2020: $80
| Janssen Biotech | Tremfya | $80 | 1 payment
|
2019: $249
| Novartis Pharmaceuticals | Cosentyx | $121 | 1 payment
|
| Allergan | None | $97 | 1 payment
|
| Boston Scientific | Watchman | $30 | 2 payments
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356870612
- Licence
- CA A171755California A171755: Current · expires 2029-02-28
- Trained
- Harvard Medical School, 2017
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207NI0002X (207NI0002X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2017-06-08
- NPI last updated
- 2024-04-15
- NPI record certified
- 2024-04-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305